What is Tango Therapeutics's cumulative cost basis?

Tango Therapeutics (TNGX) reported cumulative cost basis of $222.13M in Q1 2026.

How has Tango Therapeutics's cumulative cost basis changed year-over-year?

Tango Therapeutics's cumulative cost basis increased by 40.5% year-over-year, from $158.1M to $222.13M.

What is the long-term trend for Tango Therapeutics's cumulative cost basis?

Over 5 years (2020 to 2025), Tango Therapeutics's cumulative cost basis has grown at a 7.3% compound annual growth rate (CAGR), from $161.92M to $230.64M.

Tango Therapeutics TNGX Cumulative Cost Basis

Cumulative Cost Basis at other companies

AmgenAMGN

——

Gilead SciencesGILD

——

Lantheus HoldingsLNTH

——

ImmunityBio, Inc.IBRX

——

Tempus AI, Inc.TEM

——

Guardant HealthGH

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Enterprise value$4.43B+2,204%

P/S79.9×+74.4×

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's cumulative cost basis?: Tango Therapeutics (TNGX) reported cumulative cost basis of $222.13M in Q1 2026.
How has Tango Therapeutics's cumulative cost basis changed year-over-year?: Tango Therapeutics's cumulative cost basis increased by 40.5% year-over-year, from $158.1M to $222.13M.
What is the long-term trend for Tango Therapeutics's cumulative cost basis?: Over 5 years (2020 to 2025), Tango Therapeutics's cumulative cost basis has grown at a 7.3% compound annual growth rate (CAGR), from $161.92M to $230.64M.